StockNews.AI
REPL
StockNews.AI
19 days

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Replimune Group, Inc. of Class Action Lawsuit and Upcoming Deadlines - REPL

1. A class action lawsuit has been filed against Replimune Group, Inc. 2. The suit alleges securities fraud and unlawful business practices. 3. Replimune recently received a Complete Response Letter from the FDA. 4. The FDA found the IGNYTE trial inconclusive for approval. 5. Replimune's stock fell 77.24% following the FDA's response.

5m saved
Insight
Article

FAQ

Why Very Bearish?

The severe drop in stock price post-FDA response highlights market apprehension. Class action lawsuits can lead to further declines.

How important is it?

The article discusses active legal challenges and FDA issues, which are crucial for REPL's stock price.

Why Long Term?

The outcome of the lawsuit may have significant long-term regulatory and financial implications for REPL.

Related Companies

NVDAABBVBMY
, /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Replimune Group, Inc. ("Replimune" or the "Company")(NASDAQ: REPL). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased. The class action concerns whether Replimune and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. You have until September 22, 2025 to ask the Court to appoint you as Lead Plaintiff for the class if you purchased or otherwise acquired Replimune securities during the Class Period. A copy of the Complaint can be obtained at www.pomerantzlaw.com.         [Click here for information about joining the class action] On July 22, 2025, Replimune issued a press release "announc[ing] that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) regarding the Biologics License Application (BLA) for RP1 (vusolimogene oderparepvec) in combination with nivolumab for the treatment of advanced melanoma."  Per the press release, "[t]he CRL indicates that the FDA is unable to approve the application in its present form.  The FDA has indicated that the IGNYTE trial is not considered to be an adequate and well-controlled clinical investigation that provides substantial evidence of effectiveness.  Furthermore, the FDA said the trial cannot be adequately interpreted due to the heterogeneity of the patient population.  The CRL also states that there are items related to the confirmatory trial study design which need to be addressed, including contribution of components. Importantly, no safety issues were raised."  On this news, Replimune's stock price fell $9.52 per share, or 77.24%, to close at $2.81 per share on July 22, 2025. Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com. Attorney advertising.  Prior results do not guarantee similar outcomes.   CONTACT:Danielle PeytonPomerantz LLP[email protected]646-581-9980 ext. 7980 SOURCE Pomerantz LLP WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In

Related News